Global Liver Disease Treatment Market - 2022-2029

Market Overview

The global liver disease treatment market size was valued US$ XX million in 2020 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX% during the forecast period (2022-2029).

The liver is the largest solid organ in the human body. Furthermore, it suffers from various ailments, which are treated with a variety of products. Furthermore, these products include various types of drugs and vaccines. Anti-viral drugs, for example, are used to treat hepatitis, which causes liver inflammation. Furthermore, hepatitis is fatal, necessitating a liver transplant in some cases. Immunosuppressant drugs are used in such cases to prevent the body's rejection of the transplanted liver.

Market Dynamics

The rise in the prevalence of liver diseases such as non-alcoholic fatty liver disease (NAFLD), liver cirrhosis, hepatitis, alcoholic hepatitis, and liver cancer worldwide is largely due to an unhealthy lifestyle and excessive alcohol consumption. Furthermore, the global increase in the geriatric population contributes to disease dysfunction. As a result, there has been an increase in hospital admissions due to the liver, as mentioned above, diseases and certain hereditary genetic disorders.

An increase in alcohol consumption and unhealthy lifestyles is likely to boost market growth.

One of the key causes of liver problems is an increase in alcohol intake, as some liver cells die due to the alcohol filtering process, causing scar tissue to form in the liver. Although the liver can produce new cells, excessive drinking can disrupt this process and cause lasting harm. Alcoholic liver disease, often known as alcoholic cirrhosis, is a term that refers to three liver disorders that are associated with frequent drinking: alcoholic fatty liver, alcoholic hepatitis, and alcoholic cirrhosis.

Furthermore, poor eating habits and an unhealthy lifestyle contribute to weight growth, which leads to obesity. In adults, obesity is the leading cause of fatty liver disease, followed by alcoholism. Being overweight or obese causes fat to build in the liver. This results in liver scarring and chronic inflammation (also known as cirrhosis). Obesity is directly linked to non-alcoholic fatty liver disease (NAFLD). Excess fat causes insulin resistance and inflammatory signals. Patients with hypertension (high blood pressure), high cholesterol, are overweight or obese, and have diabetes or insulin resistance are more likely to develop fatty liver disease. According to the National Center for Biotechnology Information (NCBI), approximately 2 billion people worldwide consume alcohol, with up to 75 million diagnosed with alcohol-use disorders and at risk of alcohol-related liver disease. Nearly 2 billion adults are obese or overweight, and over 400 million have diabetes, both risk factors for non-alcoholic fatty liver disease and hepatocellular carcinoma.

In addition, the senior population is more susceptible to liver illnesses than adults due to low immune levels. Furthermore, age has been demonstrated to increase the risk of acute liver injury. Various governments non-profit organizations take initiatives, and key participants in the hepatic disorders market play a critical role in raising global awareness about liver illnesses. All of these aspects, taken together, create opportunities for R&D investments in the development of liver disease treatment solutions for improved drug efficacy and safe therapy for existing pharmaceuticals and emerging novel molecular entities, propelling the liver disease treatment market forward.

Side effects of the medications is likely to hamper the market growth

There are some side effects of antivirals medications like nausea, headache, vomiting etc. These symptoms are expected to negatively influence the liver disease treatment market as these medicines have negative effects that may cause them to be used less frequently.

COVID-19 Impact Analysis

Due to a drop in demand for several medications used in liver therapies, the COVID-19 epidemic is expected to have a mild impact. Other variables influencing the market include a lack of medical treatment, a shortage of healthcare workers, an increase in the number of COVID-19-related hospitalizations, and the availability of medications and vaccinations. However, now that COVID-19 vaccines are accessible, several governments are trying to guarantee that life-saving medications and vaccines are supplied without interruption. As a result, the market is contemplated to stabilize in the future.In contrast, research studies and activities for the treatment of liver disease by various researchers, firms, and the government, including clinical trials for efficacy and safety, strengthened the liver disease treatment market.

Segment Analysis

The antiviral drugs segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)

Antiviral medications are a type of HBV (hepatitis B virus) treatment that suppresses the viral load while lowering the risk of cirrhosis and hepatocellular cancer. Mavyret, Zepatier, and Vosevi are some of the FDA-approved medications. For many years, these medications have been widely utilized. They're safe and effective, especially for those who have signs and symptoms of moderate-to-severe liver disease or other major liver disorders and because of the COVID-19 pandemic, it has been discovered that there is presently no antiviral medicine that is directed against SARS-CoV-2, and many COVID-19 patients are given antivirals that are approved for other therapeutic reasons. Although arbidol medication does not appear to be significantly connected with liver injury consequences, a recent study published in 2021 found that the overall usage of antiviral agents increased the risk of liver injury in critically ill COVID-19 patients. Antiviral medicines commonly treat COVID-19; however, they are not suggested for seriously unwell people. The impact of antiviral therapy on liver injury in critically ill patients, on the other hand, is still unknown.

As a result, the antiviral medicine category commands a sizable market share, likely to continue throughout the projection period. The high prevalence of virus-infected liver illnesses, such as Hepatitis, is to blame. Antiviral medications are frequently used to treat hepatitis B and the long-term consequences that come with it, such as liver disease and impairment. As a result, liver transplantation and hepatocellular carcinoma are required. These factors are driving the growth of this segment.

Geographical Analysis

North America region holds the largest market share of global liver disease treatment market

North America dominates the market because of the number of research and academic institutes performing clinical trial studies in the region. The incidence of liver disease has also increased due to changing lifestyles such as increased alcohol usage and bad diets. Furthermore, regional market growth is likely to be fueled by rising patient awareness and the release of innovative products that address unmet medical needs over the forecast period. The number of deaths caused by liver illnesses has increased, as has the frequency of liver cancer. According to the Centers for Disease Control and Prevention, chronic hepatitis B infection affects between 800,000 and 1.4 million persons in the United States. In the United States, roughly 43,000 new cases of hepatitis B are diagnosed each year. Furthermore, between 15-25 percent of patients with chronic hepatitis B are at risk of developing major liver disorders like cancer, cirrhosis (liver scarring), or liver failure, which can all be fatal.

Non-alcoholic fatty liver disease (NAFLD) affects around 20% of Canadians, according to the Canadian Liver Foundation. Obesity is the leading cause of fatty liver disease in Canada. In 2018, about 30% of Canadians aged 18 and above (approximately 7.3 million persons) reported being overweight or obese based on their height and weight. This contributes to an increase in liver illnesses, raising overall market demand.

With increased prevalence of liver illnesses, liver disease management has progressed quickly. Several therapeutic alternatives are available on the market, most of which aim to avoid the course of liver disease and reduce the risk of liver morbidity and mortality. Furthermore, regional market growth is likely to be fueled by rising patient awareness and the release of innovative products that address unmet medical needs over the forecast period.

Competitive Landscape

The liver disease treatment market is fiercely competitive, with several main players. Few big firms currently dominate the market in terms of market share. Several companies have been identified to be investing in their R&D to develop unique and sophisticated therapeutic medications for liver illnesses. As a result, shortly, the industry will be driven by research and development of highly effective pharmaceutical medications with few or no adverse effects.

The companies also use organic growth techniques such as new releases, product approvals, and others such as patents and events. Some of the key players which are contributing to the growth of the market include Abbott Laboratories, Gilead Sciences, Astellas Pharmaceuticals Inc, F.Hoffmann-La Roche Ltd, AbbVie, Zydus Pharmaceuticals Inc, Eli Lilly.

The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the liver disease treatment market globally. For instance, in May 2020, Enanta Pharmaceuticals Inc. reported topline results from the INTREPID Phase 2 study of EDP-305, a Farnesoid X receptor (FXR), in patients with primary biliary cholangitis.

Key Developments

In April 2020, Alnylam Pharmaceuticals Inc. partnered with Dicerna Pharmaceuticals Inc. to develop and commercialise investigational RNAi therapeutics for the treatment of alpha-1 antitrypsin deficiency-related liver disease.

In November 2020,Roche receives EC approval for Tecentriq/Avastin for the treatment of liver cancer.

Abbott Laboratories

Overview: Abbott Laboratories (Abbott) discovers, develops, manufactures, and sells a wide range of healthcare products. The business is divided into four divisions: established pharmaceutical products, diagnostic products, nutritional products, and medical devices.

Product Portfolio:

Silymarin: Silymarin is used as adjunctive therapy in treating various types of liver disease, including acute hepatitis, chronic persistent and chronic aggressive hepatitis, cirrhosis of the liver, fatty liver, toxic metabolic or toxic metabolic liver damage. It has been demonstrated to protect the liver from general anesthesia.

Why Purchase the Report?

Visualize the composition of the global liver disease treatment market segmentation by treatment type, disease type, end user and region highlighting the key commercial assets and players.

Identify commercial opportunities in global liver disease treatment market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global liver disease treatment market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global liver disease treatment market report would provide an access to an approximately 40+ market data table, 45+ figures and 180 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers